Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-1202 in Advanced Solid Tumors
NCT05785728Phase 2Unknown
- Sponsor
- Duality Biotherapeutics
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of DB-1202 in solid tumor (advanced stage) and thyroid cancer (9 arms), sponsored by Duality Biotherapeutics. Primary endpoints: Percentage of Participants with Dose-Limiting Toxicities at 21 days, Percentage of Participants with Treatment Emergent Adverse Events at 1 year and 4 more. Status: unknown.
02
Drugs
DB-1202
03
Conditions
solid tumor (advanced stage)thyroid cancer
Beyond the preview
Go deeper on NCT05785728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785728.